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Exercise training for intermittent
claudication: a narrative review and
summary of guidelines for practitioners
Amy E Harwood ,1,2 Sean Pymer,3 Lee Ingle,4 Patrick Doherty,5 Ian C Chetter,3
Belinda Parmenter,6 Christopher D Askew,7,8 Gary A Tew9
ABSTRACT
Peripheral artery disease (PAD) is caused by atherosclerotic
narrowing of the arteries supplying the lower limbs often
resulting in intermittent claudication, evident as pain or
cramping while walking. Supervised exercise training elicits
clinically meaningful benefits in walking ability and quality
of life. Walking is the modality of exercise with the strongest
evidence and is recommended in several national and
international guidelines. Alternate forms of exercise such as
upper- or lower-body cycling may be used, if required by
certain patients, although there is less evidence for these
types of programmes. The evidence for progressive
resistance training is growing and patients can also engage
in strength-based training alongside a walking programme.
For those unable to attend a supervised class (strongest
evidence), home-based or ‘self-facilitated’ exercise
programmes are known to improve walking distance when
compared to simple advice. All exercise programmes,
independent of the mode of delivery, should be progressive
and individually prescribed where possible, considering
disease severity, comorbidities and initial exercise capacity.
All patients should aim to accumulate at least 30 min of
aerobic activity, at least three times a week, for at least
3 months, ideally in the form of walking exercise to near-
maximal claudication pain.
INTRODUCTION
Lower-limb peripheral artery disease (PAD) is
an atherosclerotic cardiovascular disease in
which the arteries that carry blood to the
legs and feet become hardened, narrowed
and/or obstructed by the build-up of
atheroma.1 PAD is a common problem
thought to affect over 200 million people
worldwide.2 The total disease prevalence is
approximately 13% of adults >50 years old,
with major risk factors including smoking,
diabetes and dyslipidaemia.3
The most classic symptom of PAD is inter-
mittent claudication (IC). This is ischaemic
muscle pain that usually presents in the calves
(but can include the thighs or buttocks), is
precipitated by exertion and relieved with rest
(figure 1).4 This pain is thought to be due to
a mismatch between the oxygen demand (of
the working muscle) and an inadequate
blood supply (due to the narrowed arterial
pathway).5
Although PAD is progressive (in the patho-
logical sense), the clinical course is relatively
stable.6 However, patients with PAD have
a higher burden of cardiovascular disease
and are at greater risk of major cardiovascular
events.7 Another major issue for many
patients is the severe decline in functional
capacity (V̇O2Peak) which are comparable to
patients with heart failure and reduced ejec-
tion fraction.8 The reduction in functional
capacity is commonly caused by a decline in
walking capacity, which may be up to less than
50% of healthy aged-matched controls.9 Fac-
tors influencing the walking distance or speed
at which symptoms occur are multifactorial
and include the site and severity of disease,
walking pace, terrain, incline and footwear.10
These physical constraints in turn have nega-
tive connotations on patient’s mental health
and there are strong associations with depres-
sion, poor quality of life (QoL) and further
avoidance of physical activity.11 12 This cycle
of activity avoidance only leads to worsening
functional ability and there is some evidence
to suggest it also leads to an elevated mortality
risk independent of disease severity and age.13
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Summary box
What is already known?
► Supervised exercise training promotes clinically
meaningful benefit in patients with intermittent
claudication.
► Walking as an exercise modality currently has the
strongest level of evidence.
What this study adds?
► A concise summary of evidence and practical
recommendations for exercise implementation for
practioners, including example protocols for exercise
training.
► Progressive resistance training may be used as
a supplement to walking programmes.
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Treatment for patients with IC involves secondary pre-
vention of cardiovascular disease risk, including smoking
cessation, diet changes, lipid modification, statin therapy,
antiplatelet therapy and management of diabetes and
hypertension. In addition to therapeutic intervention
and lifestyle modification, the primary treatment to
address the functional impairment outlined earlier is for
patients to engage in appropriate exercise training, best
achieved through a supervised exercise programme
(SEP).14 This is supported by multiple consensus guide-
lines from various governing bodies.15–17 18 However,
they lack detail and consistency (between guidelines) as
to the appropriate principles of exercise such as intensity
and progression (table 1), which impacts upon effective
implementation. In addition to inconsistencies in the
recommendations for exercise, there is also variability in
the delivery of exercise programmes globally with some
clinicians reporting lack of expertise or support to guide
the exercise delivery.19–21
This guideline for practitioners aims to accompany
these consensus guidelines to provide a succinct but
more detailed overview of, and recommendations for,
exercise prescription and training for IC. While we
appreciate that delivery and provision will vary, the key
exercise prescription components will remain and as
such, this document will be relevant for exercise practi-
tioners worldwide. In addition, we provide advice for the
implementation of the exercise prescription guidelines
into clinical practice (table 2), which also includes infor-
mation on structured alternatives when SEPs are not
available19 23
Walking ability
Measures of walking ability include pain-free and maxi-
mumwalking distance (or time) obtained during standar-
dised treadmill testing and/or the distance covered in the
6-min 30-m corridor walk test. Several treadmill protocols
have been reported, but the ‘Gardner/Skinner’ incre-
mental protocol is most commonly used.26 27 This
involves a constant speed of 3.2 km/hour at a 0% grade,
increasing by 2% every 2 min. The advantage of using
a treadmill test is that it can be standardised (ie, speed of
treadmill, grade of treadmill), although it may not be as
reflective of normal everyday walking (6-min walking
distance).28 29
Quality of life
Several generic and condition-specific questionnaires
have been used to assess QoL. Themost validated, respon-
sive and reliable questionnaires in the IC population are
the Short-Form-36 (SF-36) and King’s College Hospital’s
VascuQoL questionnaires, respectively.30 31 Additional
and commonly used questionnaires include the Walking
Impairment Questionnaire32 and the Peripheral Artery
Questionnaire.33
EXERCISE TRAINING
Benefits of exercise training
A recent Cochrane review concluded that there is high-
quality evidence showing that SEPs (a variety of regimes)
elicit important improvements in both pain-free andmax-
imum walking distance compared with no-exercise con-
trol in people with IC.14 A meta-analysis of nine trials
(n=391) showed a mean between-group difference in
pain-free walking distance at follow-up of 82 m (95% CI
72 to 92 m [follow-up ranging 6 weeks to 2 years]) and
maximum walking distance of 120 m (95% CI 50.79 to
190 m). The most commonly tested mode of exercise was
walking, with one cycling intervention. The correspond-
ing difference for maximum walking distance was 120 m
(95% CI 51 to 190 m; 10 trials, n=500). Improvements of
this magnitude are likely to represent clinically meaning-
ful changes in ambulatory function.34
The same review also reported that there was moderate-
quality evidence for improvements in physical andmental
aspects of QoL, assessed using the SF-36.14Ameta-analysis
of data at 6 months of follow-up showed the physical
component summary score to be 2 points higher in exer-
cise versus control (95% CI 1 to 3; 5 trials, n=429). The
corresponding difference for the mental component
summary score was 4 points (95% CI 3 to 5; 4 trials,
n=343). Such differences have the potential to be clini-
cally meaningful.14
Modes of exercise
In most studies, SEPs have involved treadmill or track
walking at an intensity that elicits moderate to maximal
claudication pain.35 There is a strong evidence-base for
this type of training, and clinical guidelines cite it as the
preferred modality (eg, The Trans-Atlantic Inter-Society
Consensus Document on Management of Peripheral
Arterial Disease II).15 As of 2011, alternate exercise mod-
alities had not been extensively studied.36 In 2005,
a randomised trial of 104 participants provided evidence
that a 24-week intervention of either cycling or arm-
cranking is viable alternatives for improving maximum
walking distance (shuttle-walk) up to 29% and 31%,
respectively.37 These modalities may be most useful for
patients who are unwilling/unable to walk because of
severe pain or deconditioning.38 Resistance training
may also have a complementary role (eg, for improving
muscular strength)39; however, at this point, interna-
tional guidelines suggest it should not be used as
a substitute for aerobic exercise because its impact on
Figure 1 Intermittent claudication due to peripheral artery dis-
ease. Reproduced from Morlet et al3 with permission from BMJ
Publishing Group Ltd. Note: Iliac or femoral artery disease
can cause symptoms at multiple distal muscle sites.
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Table 1 Vascular surgery guideline recommendations for exercise
Recommendation Frequency Intensity Type Time Duration Progression Supervision Location
Supplementary
exercises
Guideline
TASC II, 200715 3 × per
week
(typically)
Speed and grade
that induces
claudication within
3–5 min
Intermittent
treadmill
walking
30 min
increasing up to
60 min
Not
reported
Increase speed/
grade if patient can
walk for more than
10 min
Not reported Not
reported
Not reported
AHA/ACC, 201617 3 × per
week
Maximum–
moderate
claudication
Intermittent
walking
30–45 min
per session, with
warm up and
cool down
Minimum
of
12 weeks
Not reported Supervised by
a qualified
healthcare
professional
Hospital/
outpatient
facility
Not reported
ECS, 201718 Not
reported
Not reported Walking Minimum
3 hours/week
At least
3 months
Not reported Supervised Not
reported
Cycling, strength
training and
upper-arm
ergometry
NICE 147201816 Not
reported
Maximal pain Walking 2 hours/week 3 months Not reported Supervised Not
reported
Not reported
RACGP, 201322 3–5 × p/w Pain Intermittent
walking
30 min
increasing to
60 min
Not
reported
Not reported Supervised Not
reported
Not reported
ACC; AHA; ECS; NICE; RACGP; TASC.
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Table 2 Summary of exercise prescription recommendations
Exercise rationale
To improve walking capacity, claudication symptoms and quality of life, and for secondary
prevention of cardiovascular disease
Provider The programme should have a designated clinical lead (eg, vascular surgeon, physician or
nurse specialist). Exercise professionals who wish to work in this area should possess the
essential competencies and minimum qualifications as per the country of work. Professional
standards of accredited exercise physiologists should include detailed knowledge of
pathophysiology, exercise physiology and exercise training for patients with IC. Some of these are
specified in the following BACPR Position Statement (UK Based):http://www.bacpr.com/
resources/51A_EPG_Position_Statement.pdf
Mode of delivery The exercise should ideally be delivered through an on-site supervised programme. The exercise
prescription should be individually tailored based on an initial assessment; however, several
patients may be supervised at the same time. A facilitated, self-managed exercise programmewith
embedded behaviour change techniques is a reasonable alternative for people who prefer this
approach or are unable to access an on-site programme, or for longer-term benefit after
a supervised programme is completed. Details of a structured education programme that promotes
self-managed walking exercise can be found here.24 Additional information for home-based
exercises can be found here: (https://circulationfoundation.org.uk/news/COVID-19-special)
Unstructured, unsupervised exercise approaches that consist solely of basic advice to walk
or exercise more are not effective.
Setting On-site programmes can be delivered in various settings including hospital- or community-based
exercise physiology or physiotherapy clinics or community exercise facilities. Self-managed
programmes can be conducted in a setting that suits the individual.
Materials Assessment tools: Motorised treadmill with adjustable incline to allow incremental exercise
testing (eg, ‘Gardner’ protocol) to determine pain-free and maximum walking distances or, if
unavailable, procedures and instructions for an alternative functional capacity test (eg, 30 m 6-min
corridor walk test); questionnaires for assessing patient-perceived ambulatory function (eg,
WELCHquestionnaire), and generic and condition-specific quality of life (eg, SF-36, VascuQoL and
Walking Impairment uestionnaires, respectively). Optional—equipment to assess vascular status
(eg, ankle-brachial index) and cardiovascular disease risk (eg, blood pressure, lipid profile).
Exercise equipment: Motorised treadmills with adjustable incline or space for over-ground
walking (preferably indoor and air-conditioned). Optional for aerobic exercise—upper and lower
limb ergometers. Optional for resistance exercise—weights machines, dumbbells.
Intensity-monitoring equipment: Five-point claudication pain scale, exertion scale (eg, 6‒20point
Borg Rating of Perceived Exertion Scale), heart rate monitors, manual sphygmomanometer and
stethoscope.
Walking exercise
guidelines
Programme duration: At least 3 months
Frequency: ≥3 times/week
Claudication pain endpoint:Based on current evidence, patients should be advised to walk to the
point of near-maximum leg pain (ie, 4–5 on claudication pain scale); however, preliminary evidence
suggests that walking only to the onset of ischaemic leg pain may also be beneficial for patients
reluctant to walk at higher levels of pain
Pattern: Following a warm-up period, the patient should walk at a speed and grade that induces
claudication pain within 3–5 min. The patient is instructed to stop walking and rest when his or her
claudication pain reaches a moderate-to-strong level. When the claudication has abated, the
patient resumes walking until a moderate-to-strong claudication pain recurs. This cycle of exercise
and rest is ideally repeated for at least 30min. In subsequent visits, the speed or grade of walking is
increased if the patient is able to walk for ≥10min without reachingmoderate claudication pain. For
those patients who start at a lower level of claudication pain (1–3/5), as the patient tolerates it, they
should be encouraged to increase the intensity of pain achieved as a progression tool.
Duration per session: Many patients with IC may need to start with just 10–15 min of walking
exercise per session. In this situation, the duration of exercise should be increased by 5 min each
week, until the patient is walking for at least 30 min per session. Patients who can walk for more
than 30min per session should be encouraged to increase the exercise duration to 45–60min. They
should also be encouraged to include other modes of exercise to work on improving
cardiorespiratory fitness and muscular strength
Continued
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walking distance appears modest (eg, McDermott et al
2009). Nevertheless, there is emerging evidence to sup-
port its efficacy, and it should no longer be a mode of
exercise that is ignored. A recent systematic review and
meta-analysis (n=826; 363 resistance trained) demon-
strated that resistance training (in comparison to control)
can significantly improve both maximum walking dis-
tance via constant treadmill testing (standardised mean
difference (SMD) 0.51 [95% CI 0.23 to 0.79]) and max-
imum walking distance via progressive treadmill testing
(SMD 0.45 [95% CI 0.08 to 0.83]). Only 6-min claudica-
tion onset time (not pain-free treadmill distance) was
significantly improved with resistance training (mean dif-
ference (MD) 82 m [95% CI 40.91 to 123.54).39
Frequency of exercise
A comparison of different training frequencies for
patients with IC has not been investigated in a single
study. The 1995 meta-analysis of Gardner and Poehlman
suggested that an exercise frequency of ≥3 sessions per
week was associated with better outcomes compared with
<3 times per week, although it should be noted that it
pooled data from randomised controlled trials and
uncontrolled studies.40 In addition, the 2004 review of
Bulmer and Coombes also identified three sessions per
week as the optimal frequency for maximum improve-
ments in walking distance.41 Conversely, a meta-analysis
in 2012 including 1054 patients did not identify an opti-
mal frequency for programmes.42 The authors of the
2012 meta-analysis do note, however, that a SEP with
three sessions per week (in combination with duration
of programme and session) ‘would give the best results’.42
Therefore, frequency of SEPs should aim to be at least
three times per week, which is in line with common
physical activity guidelines for the general population.17
Duration of programme
No standardised duration of programme for patients with
IC has been identified, with exercise programme length
ranging from as little as 2 weeks to as many as
18 months.35 Gardner et al (2012) measured outcomes
at 2, 4 and 6 months (n=80) and demonstrated that
exercise-mediated improvements in pain-free and maxi-
mum walking distances were largely achieved in the first
2 months.43 Additional meta-analysis has also demon-
strated that improvements in treadmill walking occur
following 3 months of supervised exercise.41 44 45 It may
be likely that the optimal prescription is difficult to eluci-
date due to heterogeneity of studies, including differ-
ences in frequency, intensity and type of the exercise.
Currently, we recommend that programmes should be
at least a minimum of 12 weeks in duration.
Intensity of exercise
Exercise intensity is commonly prescribed on the basis of
heart rate, rating of perceived exertion, or V̇O2peak
obtained via exercise stress testing,46 andmay be classified
as low, moderate or vigorous based on the American
College of Sports Medicine guidelines.47 There is limited
information on the appropriate intensities of exercise
Exercise rationale To improve walking capacity, claudication symptoms and quality of life, and for secondary
prevention of cardiovascular disease
Upper and lower limb
ergometry
May be considered as alternative aerobic exercise strategies for improving walking ability and
quality of life. May also have the potential to provide a greater cardiorespiratory stimulus than
walking exercise in individuals with severe claudication.
Example protocol: Ten sets of 2 min of upper or lower extremity ergometry conducted twice
weekly for at least 3 months. Intensity should be moderate or Borg RPE 13–14 (6–20 scale)
Resistance exercise Though evidence is increasing, resistance exercise is yet to be included in international guidelines
as a sole therapy, it is purely recommended as an adjunct for now. It therefore should be considered
as complementary (eg, for targeting improved strength or reduced falls risk), but not as
a replacement for aerobic exercise because its impact on walking ability appears modest at best.
Example protocol: Moderate-to-high intensity (Borg exertion rating of 14–16), 6–8 exercises (leg
press, Knee flexion, knee extension, calf press, chest press, seated row) targeting themajormuscle
groups of the upper and lower body, 2–4 sets of 10–15 repetitions per set, 2–3 sessions per week.
Other Circuit-based training may be a practical way of delivering a combination of aerobic and resistance
exercises when circumstances necessitate group-based training and is an effective tool for
improving both muscle strength and cardiorespiratory fitness, which are both related to reduced
cardiovascular and all-cause mortality.25
Safety issues An initial risk assessment should occur as per Appendix E of the following ACPICR Standards
document https://www.acpicr.com/data/Page_Downloads/ACPICRStandards.pdf . Exercise is
contraindicated by foot ulcers and limb pain at rest (ie, critical limb ischaemia). As patients increase
their walking ability, there is the possibility that cardiac signs and symptoms may appear (eg,
dysrhythmia, angina). These events should prompt further clinical assessment to ensure safety
continuing. Clinical assessment should also be considered when a patient undertakes a mode of
exercise that is not limited by claudication pain.
ACPICR; BACPR; IC; RPE; SE-36, Short-Form-36; VascuQoL; WELCH.
Table 2 Continued
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programmes for patients with PAD.17 48 However, a meta-
analysis by Parmenter et al (2015) investigated the rela-
tionship between exercise intensity, V̇O2peak (ie, aerobic
capacity) and maximal walking distance, and demon-
strated that the greatest improvements occurred when
exercise intensity was between 70% and 90% HRmax
(ie, vigorous according to the American College of Sports
Medicine guidelines).49 A further systematic review by
Pymer et al (2019) focusing on high-intensity exercise
identified four studies that prescribed exercise on the
V̇O2peak or HRmax achieved during baseline testing.
Overall, six studies demonstrated significant improve-
ments in treadmill maximum walking distances com-
pared with a control group (generally consisting of
exercise advice alone).50 However, further research is
required to establish the relationship between intensity
(moderate vs vigorous) and walking improvements and
compare those findings to SEPs.
Claudication pain scale
Relatively few trials have used classically definedmeasures
of exercise intensity as described earlier, and for patients
with PAD, there is a common misconception between
exercise ‘intensity’ and severity of leg pain or
discomfort.51 Most reported trials in the literature use
the claudication pain scale to instruct patients when to
stop exercising and not exercise intensity markers such as
heart rate. The claudication pain scale is a continuous
scale from 1, indicating no pain, to 5 indicating severe
pain,49 with trials often instructing patients to walk to
near-maximal pain levels.
Three studies have specifically investigated the relation-
ship between ‘intensity’ (based on pain) and walking
outcomes.52–54Mika et al (2013) used different intensities
corresponding to scores on the pain scale and matched
exercise duration in 60 patients.53 Gardner et al (2005)
prescribed intensity as ‘high—80%’ or ‘low—40%’ based
on the maximal grade achieved at baseline in 31
patients.52 Finally, Novakovic et al (2019) randomised 36
patients to either moderate or pain-free walking, with
moderate training prescribed on 70% of the patients
predicted HRmax.54 For all studies, outcomes including
pain-free and maximum walking distance did not differ
between the intensities prescribed. This may highlight
that the volume of exercise (and not intensity prescribed)
is perhaps the most important factor for improving walk-
ing distance in patients with IC.36 49 55 With regard to
pain, overall the current evidence seems to favour
patients walking near maximal pain for beneficial out-
comes. However, walking to no pain, or minimal pain,
may also been shown to be effective for this cohort.54 55
Indeed, a meta-analysis by Parmenter et al (2011) showed
that walking without inducing claudication pain pro-
duced significant improvements in initial claudication
distance and also improved absolute claudication
distance.36 Additionally, a meta-analysis (six studies) in
2015 demonstrated that improvements in cardiorespira-
tory fitness were obtained when walking tomild pain (MD
0.79 mL/kg/min [95% CI 0.45 to 1.14]).49 Current
recommendations are if patients can tolerate, then walk-
ing to moderate pain (i.e 4–5 on the claudication scale)
may be suitable. If patients are unable to tolerate higher
levels of pain on the claudication scale, then they can walk
to low levels of pain, provided the volume of exercise is
sufficient,47 which may improve adherence levels.
Supervision
Despite consistent evidence demonstrating the clinical
effectiveness of SEPs, a European survey conducted in
2012 demonstrated that approximately 30% of the
respondents had access to a supervised programme,56
with similar availability in the UK.19 Similar evidence has
recently emerged from the USA with 54% of the respon-
dents stating no exercise to a SEP.20 These low provision
rates may be attributed to several factors including fund-
ing provision, facilities, referral pathways, resources and
a lack of trained staff.19 23
A 2014 review noted uncertainty regarding the benefits
of SEPs over unsupervised exercise, especially regarding
QoL.51 Despite the apparent superiority of SEPs, there is
still a need to develop alternative programmes, given that
supervised programmes may be ‘unpopular’ with patients
due to financial, time or transport limitations,57 58 or
simply because they are looking for a ‘quick fix’.59 As
supervised programmes may be unavailable to a large
proportion of patients, the development of alternative
home-based or ‘self-facilitated’ programmes have been
increasingly trialled. These types of interventions have
varied in content but include psychological
interventions,60 such as cognitive behavioural changes,61
step-monitoring62 and patient education.24
Home exercise programmes
Evidence for home-based or self-managed programmes is
currently conflicting. In 2013, a systematic review
reported that there was low-level evidence to suggest
home-based programmes can improve walking distance
and QoL in comparison to walking advice or non-
exercise.63 In 2018, a Cochrane review including 21 studies
and 1400 patients, reported that there was high-quality
evidence showing greater improvements in maximum
walking distance (measured via treadmill testing) at 3
months among patients enrolled in a SEP versus a home-
based programme (95% CI 0.12 to 0.65), or in patients
who received walking advice only (95% CI 0.53 to 1.07).64
This translates to walking distance improvements of
between 120 and 210 m in favour of supervised exercise,
respectively, with similar improvements maintained at 6
and 12 months. However, the prescription of exercise
may influence the magnitude of effect, possibly due to
training specificity.49 Conversely, the meta-analysis of
QoL outcomes showed no marked differences between
supervised exercise and home exercise programmes. In
a recent randomised trial, McDermott et al (2018) consid-
ered the efficacy of home-based exercise (n=99) with wear-
able technology and telephone coaching versus no
Open access
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exercise advice and found no difference home exercise
and control.65 Therefore, further research is required to
evaluate the specific components of home-based interven-
tions tomaximise patient benefit (ie, wearable technology,
on-site visits, etc).
Safety
There may be a misconception that exercise training may
be unsafe in patients with PAD. Indeed, 70% of the vas-
cular surgeons in one survey thought that cardiovascular
comorbidities or aorto-iliac stenosis or occlusions were
relative contraindications to exercise.66 Gommans et al
(2015) explored the safety of supervised exercise training
(via any exercise modality) and reviewed adverse event
data from clinical trials.67 Seventy-four trials were
included, representing 82 725 hours of training in 2876
patients with a mean age of 64 years (range 54–76 years).
Nine adverse events were reported, six of cardiac, two of
non-cardiac origin and one fatal adverse event (myocar-
dial infarction). This resulted in an all-cause complication
rate of one event per 10 340 patient-hours. The total non-
cardiac and cardiac event rate was 1 per 13 788 patients
and 1 per 41 363 hours. The study concluded that super-
vised exercise training is safe for people with IC due to
a low all-cause complication rate, and routine cardiac pre-
screening is not required.67 However, it should be noted
that patients participating in clinical trials might not be
a true representation of the overall population. This may
be due to strict exclusion/inclusion criteria screening out
patients with extensive comorbidities. It would be bene-
ficial to have observational data for adverse events in
routine SEPs, to fully elucidate the all-cause complication
rates. In addition, it is important to note, that as
a patient’s exercise tolerance, pain tolerance and walking
ability improve, this may begin to unmask underlying
signs and symptoms of coronary artery disease. While
not routine practice, cardiac screening may also be con-
sidered when patients are engaging in an exercise mod-
ality that may not elicit claudication pain such as cycling
or when they are engaging in higher-intensity exercise
programmes. In general, contraindications to participa-
tion in an exercise programme include uncontrolled
hypertension, unstable angina or other uncontrolled
arrhythmias. Relative contraindications include known
obstructive coronary disease, acquired or advance heart
block. A comprehensive list of both absolute and relative
contraindications can be found in the ‘American College
of Sports Medicine Guidelines for Exercise Testing and
Prescription’.47 68
APPLICATION TO PRACTICE
Recommendations for exercise training
All prospective patients should be clinically assessed, and
risk stratified to ensure that they do not have any contra-
indications to the exercise therapy, and to document
comorbidities that may need to be accounted for, in
order to individualise the exercise programme. Patient
ability and preference should also be taken into account
when prescribing the exercise programme. Clinical
assessment should be repeated as exercise tolerance
improves to ensure that the training intensity is sufficient
to ensure ongoing patient safety. Any exercise pro-
gramme should ideally be delivered through an on-site
supervised programme with clinical oversight. However,
a facilitated, self-managed exercise programme involving
behaviour change techniques is a reasonable alternative
for patients who prefer this approach or are unable to
access supervised exercise.24 The core modality for SEPs
should be walking; however, other modes are also effica-
cious for those who cannot tolerate walking programmes,
as outlined in table 2. Alternative modes include arm
cranking, cycling, pole-striding and progressive resistance
training. A structured programme should involve walking
at an intensity that elicits moderate-to-strong claudication
pain and should be conducted for a minimum of
3 months, involving at least three sessions of 30–45 min/
week. Initial exercise prescription should be based on
actual baseline maximum walking distance. Further evi-
dence-based recommendations for exercise training are
provided in table 2. However, if patients struggle with the
maximum intensity of pain prescribed, then walking at
lower pain levels will also lead to improvements in walking
ability/distance.36 55
During exercise training sessions, acute responses to
exercise should be monitored to inform the exercise pre-
scription, including heart rate, blood pressure (in the first
few exercise sessions), perceived exertion and claudica-
tion pain. The continuous monitoring of blood pressure
is not recommended but should be revaluated if the
intensity or mode of exercise changes. It is recommended
that heart rate may be continuously monitored, and
blood pressure, perceived exertion and claudication
pain are recorded intermittently when the patient stops
exercises (if interval walking) or if any signs or symptoms
(such as dizziness are present). Finally, programme entry
and exit assessments should be performed to determine
changes in patient outcomes, including walking distance
(primarily 6-min walk test) and QoL.
To support the provision and uptake of exercise, along-
side this guideline an infographic of key messages has
been developed that may be used as a poster or handout
in clinic; particularly where patients cannot access
a supervised programme.69
SUMMARY
Exercise training is a safe, effective and low-cost interven-
tion for improving walking ability in patients with IC.
Additional benefits may include improvements in QoL,
muscle strength and cardiorespiratory fitness. Clinical
guidelines advocate supervised exercise training as
a primary therapy for IC, with walking as the primary
modality. However, evidence is emerging for the role of
various other modes of exercise including cycling and
progressive resistance training to supplement walking
training. In addition, there is emerging evidence for
home-based exercise programmes. Revascularisation or
Open access
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drug treatment options should only be considered in
patients if exercise training provides insufficient sympto-
matic relief.
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